Evidence map›Paper›PMID 26171883›Full record

Trial reportProstate cancer and prostatic diseases2015

Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

A J Zurita, L L Pisters, X Wang, P Troncoso, P Dieringer, J F Ward, J W Davis, C A Pettaway, C J Logothetis, L C Pagliaro

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

A J ZuritaDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
L L PistersDepartment of Urology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
X WangDepartment of Biostatistics, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
P TroncosoDepartment of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
P DieringerDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
J F WardDepartment of Urology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
J W DavisDepartment of Urology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
C A PettawayDepartment of Urology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
C J LogothetisDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
L C PagliaroDepartment of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J., THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P30-CA016672NCI NIH HHS P50 CA140388
6 · The paper itself

Abstract

backgroundProstate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously demonstrated molecular characteristics of lethal cancer in the prostatectomy specimens of patients presenting with lymph node metastasis after chemohormonal treatment. Here we report the post-treatment outcomes of these patients and assess whether a link exists between surgery and treatment-free/cancer-free survival.

methodsPatients with either clinically detected lymph node metastasis or primaries at high risk for nodal dissemination were treated with androgen ablation and docetaxel. Those responding with PSA concentration <1 ng ml(-1) were recommended surgery 1 year from enrollment. ADT was withheld postoperatively. The rate of survival without biochemical progression 1 year after surgery was measured to screen for efficacy.

resultsForty patients were enrolled and 39 were evaluable. Three patients (7.7%) declined surgery. Of the remaining 36, 4 patients experienced disease progression during treatment and 4 more did not reach PSA <1. Twenty-six patients (67%) completed surgery, and 13 (33%) were also progression-free 1 year postoperatively (8 with undetectable PSA). With a median follow-up of 61 months, time to treatment failure was 27 months in the patients undergoing surgery. The most frequent patterns of first disease recurrence were biochemical (10 patients) and systemic (5).

conclusionsHalf of the patients undergoing surgery were off treatment and progression-free 1 year following completion of all therapy. These results suggest that integration of surgery is feasible and may be superior to systemic therapy alone for selected prostate cancer patients presenting with nodal metastasis.

Indexed as

ProstatectomyAdultAgedAntineoplastic Agents, HormonalDisease ProgressionHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingProstate-Specific AntigenProstatic NeoplasmsTreatment FailureTreatment OutcomeAntineoplastic Agents, HormonalProstate-Specific Antigen

Identifiers

PMID26171883
PMCPMC4821010
OpenAlexW1496368376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.